Our second-generation GcMAF is produced from serum which is carefully screened and sterilized by filtration. It has been shown to reliably activate the phagocytic activity of macrophages.
In addition, GcMAF has been found to induce the final maturation of dendritic cells (DCs). It also has an anti-angiogenic effect. This enables it to remove tumor-suppressing cells from the cancerous growths in a malignant tumour.
Activation of Macrophages
GcMAF is a naturally occurring glycoprotein found in cells that activates macrophages, which are specialized phagocytic (engulf and digest) white blood cells that destroy microbes and cancer cells. Macrophages play an important role in non-specific innate defense mechanisms as well as in facilitating the specific immune response against pathogens and cancers by activating lymphocytes and other immune system cells.
Gc MAF is produced by enzymatically treating purified vitamin D binding protein with immobilized column-immobilized b-galactosidase and sialidase to convert it into its most potent form, macrophage activating factor (MAF) [31]. It is then filter sterilized and administered weekly intramuscularly or intravenously resulting in a substantial and permanent level of phagocytosis and superoxide production.
Macrophages that have been activated with GcMAF develop a considerable variation of receptors which recognize tumor cell surface abnormalities and kill malignant cells. Curative rates have been observed in patients with breast, prostate and head/neck cancers as well as in those infected with HIV-1 requiring less than 22 weeks of treatment.
Anti-Inflammatory Effects
GcMAF activates macrophages and generates superoxide free radicals to kill cancer cells and other pathogens. It also prevents tumors from growing by inhibiting angiogenesis.
It does so by preventing cells that produce proangiogenic molecules from binding to and activating macrophages. This reduces the ability of angiogenic factors to promote the development of new blood vessels that supply the tumor with nutrients and oxygen.
A study of 16 prostate cancer patients showed that a weekly injection of GcMAF decreased serum a-N-acetylgalactosaminidase (Nagalase) levels. By the end of 7 years, all 16 patients were cancer-free and had low Nagalase activity in their blood.
However, these results haven’t been verified with the kind of randomized controlled trials used to approve medications in the U.S. And it’s important to note that GcMAF isn’t FDA-approved. It is sold in supplements and on social media websites to avoid government regulation. These products can be dangerous, and some people who use them have experienced high-grade fever and eczema.
Anti-Cancer Effects
GcMAF is a potent mitogenic factor that stimulates the myeloid progenitor cells to increase systemic macrophage cell counts by 40-fold in four days. The resulting highly activated macrophages are tumoricidal, able to destroy cancerous cells and inhibit angiogenesis.
It has also been reported that GcMAF is able to directly deglycosylate the malignant cell protein nagalase, which is one of the mechanisms by which cancers evade immune response. GcMAF has been shown to be a powerful immunotherapy with curative effects on various types of cancer including prostate, breast, colon, lung (including mesothelioma), liver and kidney.
Time course analyses of serum Nagalase activity before and after weekly GcMAF administration have revealed that the MAF precursor activity correlates inversely with PSA levels. This indicates that as the GcMAF therapy progresses, PSA levels decrease and Nagalase activities also decline in a linear manner. However, the researchers that produced these retracted studies did not analyze PSA or use any other established methods to determine whether their injected GcMAF actually activated macrophages in the blood of patients.
Anti-Viral Effects
The Medicines and Healthcare products Regulatory Agency (MHRA) has warned people not to buy GcMAF from companies selling it online. It has not been regulated and may pose a significant risk to health. It says anyone who uses it should seek professional medical advice. It adds that any GcMAF sold from outside the UK is likely to be made with unclean ingredients or may be contaminated. It has told the National Autistic Society it is “extremely concerned” by reports of companies selling unlicensed GcMAF.
It is thought to have anti-viral properties and could help fight viruses like hepatitis C and influenza, and potentially HIV and SARS CoV-2. gcmaf works by binding to the GalNAc residues on the surface of inflamed B cells and deglycosylating them with immobilized b-galactosidase and sialidase. This process produces a molecule that activates macrophages and has been shown to have anti-viral effects on tumour cells. It also has immunosuppressive effects in AIDS patients.